Psychotherapy for major depressive disorder and generalized anxiety disorder: A health technology assessment

Ontario Health Technology Assessment Series

Volumn 17, Issue 15, 2017, Pages 1-167

 

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT;

ANXIETY DISORDER; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BUDGET; COGNITIVE BEHAVIORAL THERAPY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DAILY LIFE ACTIVITY; EVIDENCE BASED MEDICINE; FUNDING; GROUP THERAPY; HEALTH CARE COST; HUMAN; INTERPERSONAL THERAPY; INTERVIEW; MAJOR DEPRESSION; ONTARIO; OUTPATIENT; PARAMEDICAL PERSONNEL; PERSONAL EXPERIENCE; PERSONALIZED MEDICINE; PHYSICIAN; PROBABILITY; PSYCHOTHERAPY; QUALITY OF LIFE; RECURRENT DISEASE; RELAPSE; SCORING SYSTEM; SUPPORTIVE THERAPY; SURVIVAL; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; COST BENEFIT ANALYSIS; ECONOMICS; PROCEDURES; QUALITY ADJUSTED LIFE YEAR;

ANXIETY DISORDERS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHOTHERAPY; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 85050427682     PISSN: 19157398     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (163)

1. Levav I, Rutz W. The WHO World Health Report 2001 new understanding-new hope. Isr J Psychiatry Relat Sci. 2002;39(1):50-6.
2. Patten SB, Kennedy SH, Lam RW, O’Donovan C, Filteau MJ, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. J Affect Disord. 2009;117 Suppl 1:S5-14.
3. American Psychiatric Assocation. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): The Association; 2013.
4. Swinson R, Antony MM, Bleau P, Chokta P, Craven MA, Fallu A, et al. Management of anxiety disorders. Can J Psychiatry. 2006;51 Suppl 2:1-92S.
5. World Health Organization. ICD-10, the ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva (Switzerland): The Organization; 2010.
6. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-105.
7. Churchill R, Moore HMT, Furukawa TA, Caldwell DM, Davies P, Jones H, et al. ‘Third wave’ cognitive and behavioural therapies versus treatment as usual for depression. Cochrane Database of Systematic Reviews. 2013(10).
8. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord. 2009;117 Suppl 1:S1-2.
9. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117 Suppl 1:S26-43.
10. Parikh SV, Segal ZV, Grigoriadis S, Ravindran AV, Kennedy SH, Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord. 2009;117 Suppl 1:S15-25.
11. Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev. 2007(1):Cd001848.
12. Centre for Addiction and Mental Health. About therapy. Challenges and choices: finding mental health services in Ontario [Internet]. Toronto (ON): The Centre; 2012 [cited 2017 Feb]. Available from: http://www.camh.ca/en/hospital/visiting_camh/rights_and_policies/Pages/challenges_choices_abouttherapy.aspx
13. Royal Australian and New Zealand College of Psychiatrists. Structured psychotherapy requirements [Internet]. Melbourne (Australia): The College; 2017 [cited 2017 Feb]. Available from: https://www.ranzcp.org/Files/PreFellowship/2012-Fellowship-Program/Adult-Certificate/Structured-psychotherapy-requirements.aspx
14. Cuijpers P, Driessen E, Hollon SD, van Oppen P, Barth J, Andersson G. The efficacy of non-directive supportive therapy for adult depression: a meta-analysis. Clin Psychol Rev. 2012;32(4):280-91.
15. U.S. Centers for Medicare and Medicaid Services. Your Medicare coverage: is my test, item or service covered? Mental health care (outpatient) [Internet]. Baltimore (MD): The Centers; 2017 [cited 2017 Feb]. Available from: https://www.medicare.gov/coverage/outpatient-mental-health-care.html
16. Health Quality Ontario. Health technology assessments: methods and process guide [Internet]. Toronto (ON): Queen’s Printer for Ontario; 2017 Mar [cited 2017 May 7]. Available from: http://www.hqontario.ca/Portals/0/documents/evidence/reports/hta-methods-and-process-guide-en.pdf
17. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40-6.
18. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
20. Cuijpers P, Cristea IA, Karyotaki E, Reijnders M, Huibers MJH. How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence. World Psychiatry. 2016;15(3):245-58.
21. Linde K, Sigterman K, Kriston L, Rucker G, Jamil S, Meissner K, et al. Effectiveness of psychological treatments for depressive disorders in primary care: systematic review and meta-analysis. Ann Fam Med. 2015;13(1):56-68.
22. Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A, et al. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. Health Technol Assess. 2001;5(35):1-173.
23. Laidlaw K, Davidson K, Toner H, Jackson G, Clark S, Law J, et al. A randomised controlled trial of cognitive behaviour therapy vs treatment as usual in the treatment of mild to moderate late life depression. Int J Geriatr Psychiatry. 2008;23(8):843-50.
24. Scott AI, Freeman CP. Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks. BMJ. 1992;304(6831):883-7.
25. Scott C, Tacchi MJ, Jones R, Scott J. Acute and one-year outcome of a randomised controlled trial of brief cognitive therapy for major depressive disorder in primary care. Br J Psychiatry. 1997;171:131-4.
26. Smit A, Kluiter H, Conradi HJ, van der Meer K, Tiemens BG, Jenner JA, et al. Short-term effects of enhanced treatment for depression in primary care: results from a randomized controlled trial. Psychol Med. 2006;36(1):15-26.
27. Teasdale JD, Fennell MJ, Hibbert GA, Amies PL. Cognitive therapy for major depressive disorder in primary care. Br J Psychiatry. 1984;144:400-6.
28. Ross M, Scott M. An evaluation of the effectiveness of individual and group cognitive therapy in the treatment of depressed patients in an inner city health centre. J R Coll Gen Pract. 1985;35(274):239-42.
29. Biesheuvel-Leliefeld KE, Kok GD, Bockting CL, Cuijpers P, Hollon SD, van Marwijk HW, et al. Effectiveness of psychological interventions in preventing recurrence of depressive disorder: meta-analysis and meta-regression. J Affect Disord. 2015;174:400-10.
30. Clarke K, Mayo-Wilson E, Kenny J, Pilling S. Can non-pharmacological interventions prevent relapse in adults who have recovered from depression? A systematic review and meta-analysis of randomised controlled trials. Clin Psychol Rev. 2015;39:58-70.
31. Guidi J, Tomba E, Fava GA. The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry. 2016;173(2):128-37.
32. Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry. 2001;58(4):381-8.
33. Jarrett RB, Kraft D, Schaffer M, Witt-Browder A, Risser R, Atkins DH, et al. Reducing relapse in depressed outpatients with atypical features: a pilot study. Psychother Psychosom. 2000;69(5):232-9.
34. Jarrett RB, Minhajuddin A, Gershenfeld H, Friedman ES, Thase ME. Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo. JAMA Psychiatry. 2013;70(11):1152-60.
35. Karyotaki E, Smit Y, Holdt Henningsen K, Huibers MJ, Robays J, de Beurs D, et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. J Affect Disord. 2016;194:144-52.
36. Amick HR, Gartlehner G, Gaynes BN, Forneris C, Asher G, Morgan LC, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015;351:h6019.
37. Cuijpers P, Hollon SD, Van Straten A, Bockting C, Berking M, Andersson G. Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open [Internet]. 2013 [cited 2017 Jul 7];3(4):e002542. Available from: http://bmjopen.bmj.com/content/3/4/e002542
38. Cuijpers P, Sijbrandij M, Koole S, Huibers M, Berking M, Andersson G. Psychological treatment of generalized anxiety disorder: a meta-analysis. Clin Psychol Rev. 2014;34(2):130-40.
39. Barlow D, Rapee R, Brown T. Behavioral treatment of generalized anxiety disorder. Behav Ther. 1992;23(4):551-70.
40. Butler G, Fennell M, Robson P, Gelder M. Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol. 1991;59(1):167-75.
41. Dugas MJ, Ladouceur R, Leger E, Freeston MH, Langlois F, Provencher MD, et al. Group cognitive-behavioral therapy for generalized anxiety disorder: treatment outcome and long-term follow-up. J Consult Clin Psychol. 2003;71(4):821-5.
42. Ladouceur R, Dugas MJ, Freeston MH, Leger E, Gagnon F, Thibodeau N. Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: evaluation in a controlled clinical trial. J Consult Clin Psychol. 2000;68(6):957-64.
43. Mohlman J, Gorenstein EE, Kleber M, de Jesus M, Gorman JM, Papp LA. Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigations. Am J Geriatr Psychiatry. 2003;11(1):24-32.
44. Stanley MA, Hopko DR, Diefenbach GJ, Bourland SL, Rodriguez H, Wagener P. Cognitive-behavior therapy for late-life generalized anxiety disorder in primary care: preliminary findings. Am J Geriatr Psychiatry. 2003;11(1):92-6.
45. Wetherell JL, Gatz M, Craske MG. Treatment of generalized anxiety disorder in older adults. J Consult Clin Psychol. 2003;71(1):31-40.
46. Jakobsen JC, Hansen JL, Simonsen E, Gluud C. The effect of interpersonal psychotherapy and other psychodynamic therapies versus ‘treatment as usual’ in patients with major depressive disorder. PLoS One. 2011;6(4):e19044.
47. Schulberg HC, Block MR, Madonia MJ, Scott CP, Rodriguez E, Imber SD, et al. Treating major depression in primary care practice: eight-month clinical outcomes. Arch Gen Psychiatry. 1996;53(10):913-9.
48. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851-5.
49. Schramm E, van Calker D, Dykierek P, Lieb K, Kech S, Zobel I, et al. An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: acute and long-term results. Am J Psychiatry. 2007;164(5):768-77.
50. Fuchs CZ, Rehm LP. A self-control behavior therapy program for depression. J Consult Clin Psychol. 1977;45(2):206-15.
51. Shaw BF. Comparison of cognitive therapy and behavior therapy in the treatment of depression. J Consult Clin Psychol. 1977;45(4):543-51.
52. Nezu AM. Efficacy of a social problem-solving therapy approach for unipolar depression. J Consult Clin Psychol. 1986;54(2):196-202.
53. Cuijpers P, Koole SL, van Dijke A, Roca M, Li J, Reynolds CF, 3rd. Psychotherapy for subclinical depression: meta-analysis. Br J Psychiatry. 2014;205(4):268-74.
54. Driessen E, Hollon SD, Bockting CL, Cuijpers P, Turner EH. Does publication bias inflate the apparent efficacy of psychological treatment for major depressive disorder? A systematic review and meta-analysis of US National Institutes of Health-funded trials. PLoS One. 2015;10(9):e0137864.
55. Heuzenroeder L, Donnelly M, Haby MM, Mihalopoulos C, Rossell R, Carter R, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust N Z J Psychiatry. 2004;38(8):602-12.
56. Vos T, Corry J, Haby MM, Carter R, Andrews G. Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression. Aust N Z J Psychiatry. 2005;39(8):683-92.
57. Brown JS, Sellwood K, Beecham JK, Slade M, Andiappan M, Landau S, et al. Outcome, costs and patient engagement for group and individual CBT for depression: a naturalistic clinical study. Behav Cogn Psychother. 2011;39(3):355-8.
58. Bosmans JE, van Schaik DJ, Heymans MW, van Marwijk HW, van Hout HP, de Bruijne MC. Cost-effectiveness of interpersonal psychotherapy for elderly primary care patients with major depression. Int J Technol Assess Health Care. 2007;23(4):480-7.
59. Scott J, Palmer S, Paykel E, Teasdale J, Hayhurst H. Use of cognitive therapy for relapse prevention in chronic depression. Cost-effectiveness study. Br J Psychiatry. 2003;182:221-7.
60. Revicki DA, Siddique J, Frank L, Chung JY, Green BL, Krupnick J, et al. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women. Arch Gen Psychiatry. 2005;62(8):868-75.
61. Simon J, Pilling S, Burbeck R, Goldberg D. Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline. Br J Psychiatry. 2006;189:494-501.
62. Sava FA, Yates BT, Lupu V, Szentagotai A, David D. Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial. J Clin Psychol. 2009;65(1):36-52.
63. Sado M, Knapp M, Yamauchi K, Fujisawa D, So M, Nakagawa A, et al. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Aust N Z J Psychiatry. 2009;43(6):539-47.
64. Holman AJ, Serfaty MA, Leurent BE, King MB. Cost-effectiveness of cognitive behaviour therapy versus talking and usual care for depressed older people in primary care. BMC Health Serv Res. 2011;11:33.
65. Prukkanone B, Vos T, Bertram M, Lim S. Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand. Value Health. 2012;15(1 Suppl):S3-8.
66. Kafali N, Cook B, Canino G, Alegria M. Cost-effectiveness of a randomized trial to treat depression among Latinos. J Ment Health Policy Econ. 2014;17(2):41-50.
67. Hollinghurst S, Carroll FE, Abel A, Campbell J, Garland A, Jerrom B, et al. Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial. Br J Psychiatry. 2014;204(1):69-76.
68. Wiles NJ, Thomas L, Turner N, Garfield K, Kounali D, Campbell J, et al. Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial. Lancet Psychiatry. 2016;3(2):137-44.
69. Koeser L, Donisi V, Goldberg DP, McCrone P. Modelling the cost-effectiveness of pharmacotherapy compared with cognitive-behavioural therapy and combination therapy for the treatment of moderate to severe depression in the UK. Psychol Med. 2015;45(14):3019-31.
70. Wiles N, Thomas L, Abel A, Barnes M, Carroll F, Ridgway N, et al. Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial. Health Technol Assess. 2014;18(31):1-167.
71. Lam RW, Kennedy SH, Parikh SV, MacQueen GM, Milev RV, Ravindran A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods. Can J Psychiatry. 2016;61(9):506-9.
72. Brien S, Grenier L, Kapral ME, Kurdyak P, Vigod S, for Health Quality Ontario and Institute for Clinical Evaluative Sciences. Taking stock: a report on the quality of mental health and addictions services in Ontario. An HQO/ICES report. Toronto (ON): Queen’s Printer for Ontario; 2015.
73. Jacobs P, Dewa C, Lesage A, Vasiliadis H-M, Escober C, Mulvale G, et al. The cost of mental health and substance abuse services in Canada. Edmonton (AB): Institute of Health Economics; 2010.
74. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547.
75. Patten SB, Williams JV, Lavorato DH, Wang JL, McDonald K, Bulloch AG. Descriptive epidemiology of major depressive disorder in Canada in 2012. Can J Psychiatry. 2015;60(1):23-30.
76. Kurdyak P, Stukel TA, Goldbloom D, Kopp A, Zagorski BM, Mulsant BH. Universal coverage without universal access: a study of psychiatrist supply and practice patterns in Ontario. Open Med. 2014;8(3):e87-99.
77. Goldner EM, Jones W, Fang ML. Access to and waiting time for psychiatrist services in a Canadian urban area: a study in real time. Can J Psychiatry. 2011;56(8):474-80.
78. Payne KA, Myhr G. Increasing access to cognitive-behavioural therapy (CBT) for the treatment of mental illness in Canada: a research framework and call for action. Healthc Policy. 2010;5(3):e173-85.
79. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231-50.
80. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 4th ed [Internet]. Ottawa (ON): The Agency; 2017 [cited 2017 Apr 4]. Available from: https://www.cadth.ca/guidelines-economic-evaluation-health-technologies-canada-4th-edition
81. Patten SC. The duration of major depressive episodes in the Canadian general population. Chronic Dis Can. 2001;22(1):6-11.
82. Patten SB. Recurrence risk in major depression. Depress Anxiety. 2013;30(1):1-4.
83. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737-44.
84. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540-60.
85. Lam RW, McIntosh D, Wang J, Enns MW, Kolivakis T, Michalak EE, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and principles of care. Can J Psychiatry. 2016;61(9):510-23.
86. Parikh SV, Quilty LC, Ravitz P, Rosenbluth M, Pavlova B, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. Psychological treatments. Can J Psychiatry. 2016;61(9):524-39.
87. Patten SB. Updated CANMAT guidelines for treatment of major depressive disorder. Can J Psychiatry. 2016;61(9):504-5.
88. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-7.
89. National Institute for Health and Clinical Excellence. Generalised anxiety disorder and panic disorder in adults: management. London (UK): The Institute; 2011.
90. National Institute for Health and Clinical Excellence. Depression in adults: recognition and management. London (UK): The Institute; 2009.
91. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. 2006;51(8 Suppl 2):9-91s.
92. MacQueen GM, Frey BN, Ismail Z, Jaworska N, Steiner M, Lieshout RJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. Can J Psychiatry. 2016;61(9):588-603.
93. Milev RV, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation treatments. Can J Psychiatry. 2016;61(9):561-75.
94. Pare M, Gilbert B. Psychological therapy and counseling. Toronto (ON): Ontario Guidelines Advisory Committee; 2002.
95. Health Quality Ontario. Major depression: care for adults and adolescents [Internet]. Toronto (ON): Queen’s Printer for Ontario; 2016 [cited 2017 Apr 18]. Available from: http://www.hqontario.ca/portals/0/documents/evidence/quality-standards/qs-depression-clinical-guide-1609-en.pdf
96. Interpersonal Psychotherapy Institute. About IPT [Internet]. Coralville (IA): The Institute; 2017 [cited 2017 Jan 18]. Available from: https://iptinstitute.com/about-ipt/
97. Statistics Canada. Consumer price index, health and personal care, by province (Canada) [Internet]. Ottawa (ON): Statistics Canada; 2016 [cited 2017 Jan 18]. Available from: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ161a-eng.htm
98. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62 Suppl 16:5-9.
99. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Recurrence of major depressive disorder and its predictors in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol Med. 2013;43(1):39-48.
100. Eaton WW, Shao H, Nestadt G, Lee HB, Bienvenu OJ, Zandi P. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008;65(5):513-20.
101. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156(7):1000-6.
102. Khan A, Schwartz K. Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports. Ann Clin Psychiatry. 2007;19(1):31-6.
103. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160(4):790-2.
104. Statistics Canada. Life tables, Canada, provinces and territories (2009 to 2011, no. 5) [Internet]. Ottawa (ON): Statistics Canada; 2011 [cited 2017 Aug 3]. Available from: http://www.statcan.gc.ca/access_acces/alternative_alternatif.action?loc=http://www.statcan.gc.ca/pub/84-537-x/2013005/tbl_2009_2011-eng.xlsx
105. Gartlehner G, Gaynes BN, Amick HR, Asher GN, Morgan LC, Coker-Schwimmer E, et al. Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: an evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;164(5):331-41.
106. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-58.
107. Williams N, Simpson AN, Simpson K, Nahas Z. Relapse rates with long-term antidepressant drug therapy: a meta-analysis. Hum Psychopharmacol. 2009;24(5):401-8.
108. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. Chichester (UK): John Wiley & Sons Ltd.; 2009.
109. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press; 2005.
110. Mohiuddin S, Payne K. Utility values for adults with unipolar depression: systematic review and meta-analysis. Med Decis Making. 2014;34(5):666-85.
111. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord. 1998;48(1):25-36.
112. Schaffer A, Levitt AJ, Hershkop SK, Oh P, MacDonald C, Lanctot K. Utility scores of symptom profiles in major depression. Psychiatry Res. 2002;110(2):189-97.
113. Lenert LA, Sherbourne CD, Sugar C, Wells KB. Estimation of utilities for the effects of depression from the SF-12. Med Care. 2000;38(7):763-70.
114. King M, Sibbald B, Ward E, Bower P, Lloyd M, Gabbay M, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. Health Technol Assess. 2000;4(19):1-83.
115. Mann R, Gilbody S, Richards D. Putting the ‘Q’ in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures. Soc Psychiatry Psychiatr Epidemiol. 2009;44(7):569-78.
116. Vallejo-Torres L, Castilla I, Gonzalez N, Hunter R, Serrano-Perez P, Perestelo-Perez L. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model. Psychol Med. 2015;45(7):1459-70.
117. Ministry of Health and Long-Term Care. Schedule of benefits: physician services under the Health Insurance Act [Internet]. Toronto (ON): The Ministry; 2015 [cited 2017 Aug 1]. Available from: http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master20160401.pdf
118. Kates N, McPherson-Doe C, George L. Integrating mental health services within primary care settings: the Hamilton Family Health Team. J Ambul Care Manage. 2011;34(2):174-82.
119. Rosser WW, Colwill JM, Kasperski J, Wilson L. Patient-centered medical homes in Ontario. N Engl J Med. 2010;362(3):e7.
120. Rosser WW, Colwill JM, Kasperski J, Wilson L. Progress of Ontario’s family health team model: a patient-centered medical home. Ann Fam Med. 2011;9(2):165-71.
121. Association of Family Health Teams of Ontario. Optimizing value of and access to team-based primary care [Internet]. Toronto (ON): The Association; 2015 Jun 4 [cited 2016 Nov 16]. Available from: http://www.afhto.ca/highlights/evidence/optimizing-value-of-and-access-to-team-based-primary-care/
122. Canadian Agency for Drugs and Technologies in Health. Guidance document for the costing of health care resources in the Canadian setting. 2nd ed [Internet]. Ottawa (ON): The Agency; 2016 Jun [cited 2017 Apr 4]. Available from: https://www.cadth.ca/guidance-document-costing-health-care-resources-canadian-setting
123. Association of Family Health Teams of Ontario. Toward a primary care recruitment and retention strategy for Ontario. Toronto (ON): The Association; 2014.
124. Gidwani RA. A budget impact analysis of chronic disease screening: the business care of rapid HIV testing in VA emergency departments. Ann Arbor (MI): UMI Dissertation Publishing; 2009.
125. Ontario Ministry of Health and Long-Term Care. Ontario drug benefit formulary/comparative drug index [Internet]. Toronto (ON): The Ministry; 2015 [cited 2017 Aug 3]. Available from: https://www.formulary.health.gov.on.ca/formulary/
126. Alberta College of Family Physicians. Price comparison of commonly prescribed pharmaceuticals in Alberta 2014 [Internet]. Edmonton (AB): The College; 2014 [cited 2017 Apr 4]. Available from: https://www.acfp.ca/wp-content/uploads/2014/06/ACFPPricingDoc2014.pdf
127. Health Quality Ontario. Repetitive transcranial magnetic stimulation for treatment-resistant depression: an economic analysis. Ont Health Technol Assess Ser. 2016;16(6):1-51.
128. de Oliveira C, Cheng J, Vigod S, Rehm J, Kurdyak P. Patients with high mental health costs incur over 30 percent more costs than other high-cost patients. Health Aff (Millwood). 2016;35(1):36-43.
129. Bereza BG, Machado M, Papadimitropoulos M, Sproule B, Ravindran AV, Einarson TR. A Markov model approach assessing the cost of illness of generalized anxiety disorder in Canada. Neurol Ther. 2012;1(1).
130. Kolber MC, Lee J, Nickonchuk T. Price comparison of commonly prescribed pharmaceuticals in Alberta 2014 [Internet]. Edmonton (AB): Alberta College of Family Physicians; 2014 [cited 2017 Aug 3]. Available from: https://www.acfp.ca/wp-content/uploads/2014/06/ACFPPricingDoc2014.pdf
131. O’Brien BJ, Briggs AH. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res. 2002;11(6):455-68.
132. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices-overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32(5):667-77.
133. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making. 2012;32(5):690-700.
134. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479-500.
135. Stinnett AA, Mullahy J. The negative side of cost-effectiveness analysis. JAMA. 1997;277(24):1931-2; author reply 2-3.
136. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making. 1994;14(3):259-65.
137. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med. 2006;62(9):2091-100.
138. Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA. 2007;298(2):221-4.
139. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22(5):417-30.
140. Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ. 2004;13(5):405-15.
141. Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5-14.
142. Patten SB, Williams JV, Lavorato DH, Wang JL, McDonald K, Bulloch AG. Major depression in Canada: what has changed over the past 10 years? Can J Psychiatry. 2016;61(2):80-5.
143. Wang J, Williams J, Lavorato D, Schmitz N, Dewa C, Patten SB. The incidence of major depression in Canada: the National Population Health Survey. J Affect Disord. 2010;123(1-3):158-63.
144. Patten SB, Lee RC. Refining estimates of major depression incidence and episode duration in Canada using a Monte Carlo Markov model. Med Decis Making. 2004;24(4):351-8.
145. Patten SB, Lee RC. Describing the longitudinal course of major depression using Markov models: data integration across three national surveys. Population health metrics. 2005;3:11.
146. Statistics Canada. Table 051-0001 - Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual (persons unless otherwise noted), CANSIM (database) [Internet]. Ottawa (ON): Statistics Canada; 2016 [cited 2017 Aug 3]. Available from: http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=0510001&pattern=&stByVal=1&p1=1&p2=37&tabMode=dataTable&csid=
147. Farrar S, Kates N, Crustolo AM, Nikolaou L. Integrated model for mental health care. Are health care providers satisfied with it? Can Fam Physician. 2001;47:2483-8.
148. Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry. 2006;51(2):100-13.
149. Watterson RA, Williams JV, Lavorato DH, Patten SB. Descriptive epidemiology of generalized anxiety disorder in Canada. Can J Psychiatry. 2016 Jul 10;62(1):24-9.
150. Barham L. Public and patient involvement at the UK National Institute for Health and Clinical Excellence. Patient. 2011;4(1):1-10.
151. Messina J, Grainger DL. A pilot study to identify areas for further improvements in patient and public involvement in health technology assessments for medicines. Patient. 2012;5(3):199-211.
152. Ontario Patient Engagement Subcommittee. Public engagement for health technology assessment at Health Quality Ontario-final report from the Ontario Health Technology Advisory Committee Public Engagement Subcommittee. [Internet]. Toronto (ON): Queen’s Printer for Ontario; 2015 Apr [cited 2017 Jul 11]. Available from: http://www.hqontario.ca/Portals/0/documents/evidence/special-reports/report-subcommittee-20150407-en.pdf
153. Tjornhoj-Thomsen T, Hansen HP. Knowledge in health technology assessment: who, what, how? Int J Technol Assess Health Care. 2011;27(4):324-9.
154. Rowe G, Frewer LJ. A typology of public engagement mechanisms. Sci Technol Hum Val. 2005;30(2):251-90.
155. Brundisini F, Giacomini M, DeJean D, Vanstone M, Winsor S, Smith A. Chronic disease patients’ experiences with accessing health care in rural and remote areas: a systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser. 2013;13(15):1-33.
156. Kvale S. Interviews: an introduction to qualitative research interviewing. Thousand Oaks (CA): Sage Publications; 1996.
157. Kuzel AJ. Sampling in qualitative inquiry. In: Miller WL, Crabtree BF, editors. Doing qualitative research. Thousand Oaks (CA): Sage Publications; 1999. p. 33-45.
158. Morse J. Emerging from the data: cognitive processes of analysis in qualitative research. In: Morse J, editor. Critical issues in qualitative research methods Thousand Oaks (CA): Sage Publications; 1994. p. 23-41.
159. Patton MQ. Qualitative research and evaluation methods. 3rd ed. Thousand Oaks (CA): Sage Publications; 2002.
160. Strauss AL, Corbin JM. Basics of qualitative research: techniques and procedures of developing a grounded theory. 2nd ed. Thousand Oaks (CA): Sage Publications; 1998.
161. Health Technology Assessment International. Introduction to health technology assessment [Internet]. Edmonton (AB): Health Technology Assessment International; 2015 [cited 2017 Feb]. Available from: http://www.htai.org/fileadmin/HTAi_Files/ISG/PatientInvolvement/v2_files/Resource/PCISG-Resource-Intro_to_HTAKFaceyJun13.pdf
162. Strauss AL, Corbin JM. Grounded theory research: procedures, canons, and evaluative criteria. Qual Sociol. 1990;13(1):3-21.
163. Strauss AL, Corbin JM. Grounded theory methodology: an overview. In: Denzin NK, Lincoln YS, editors. Handbook of qualitative research. Thousand Oaks (CA): Sage Publications; 1994. p. 273-85.